Minimizing Glucose Excursions (GEM) With Continuous Glucose Monitoring in Type 2 Diabetes: A Randomized Clinical Trial
Daniel J Cox, Tom Banton, Matthew Moncrief, Mark Conaway, Anne Diamond, Anthony L McCall, Daniel J Cox, Tom Banton, Matthew Moncrief, Mark Conaway, Anne Diamond, Anthony L McCall
Abstract
This study aimed to compare conventional medication management of type 2 diabetes (T2D) to medication management in conjunction with a lifestyle intervention using continuous glucose monitoring to minimize glucose excursions. Thirty adults (63% female; mean age, 53.3 years) who were diagnosed with T2D for less than 11 years (mean, 5.6 years), had glycated A1c (HbA1c) ≥ 7.0% (51 mmol/mol) (mean 8.8%, [73 mmol/mol]), and were not using insulin, were randomly assigned in a 1:2 ratio to routine care (RC) or 4 group sessions of glycemic excursion minimization plus real-time CGM (GEMCGM). Assessments at baseline and 5 months included a physical exam, metabolic and lipid panels, a review of diabetes medications, and psychological questionnaires. For the week following assessments, participants wore a blinded activity monitor and completed 3 days of 24-hour dietary recall. A subgroup also wore a blinded CGM. GEMCGM participants significantly improved HbA1c (from 8.9% to 7.6% [74-60 mmol/mol] compared with 8.8% to 8.7% [73-72 mmol/mol] for RC (P = .03). Additionally, GEMCGM reduced the need for diabetes medication (P = .01), reduced carbohydrate consumption (P = .009), and improved diabetes knowledge (P = .001), quality of life (P = .01) and diabetes distress (P = .02), and trended to more empowerment (P = .05) without increasing dietary fat, lipids, or hypoglycemia. Confirming our prior research, GEMCGM appears to be a safe, effective lifestyle intervention option for adults with suboptimally controlled T2D who do not take insulin.
Keywords: continuous glucose monitoring; exercise; glycemic load; physical activities; postprandial blood glucose; type 2 diabetes mellitus.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.
Figures
References
- Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.
- American Diabetes Association (ADA). Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1): S1-S212.
- Cox DJ, Taylor AG, Singh H, et al. Glycemic load, exercise, and monitoring blood glucose (GEM): a paradigm shift in the treatment of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016;111:28-35.
- Ceriello A, Davidson J, Hanefeld M, et al. ; International Prandial Glucose Regulation Study Group . Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis. 2006;16(7):453-456.
- Polonsky WH, Fisher L. Self-monitoring of blood glucose in noninsulin-using type 2 diabetic patients: right answer, but wrong question: self-monitoring of blood glucose can be clinically valuable for noninsulin users. Diabetes Care. 2013;36(1):179-182.
- Cox DJ, Basu R, McCall A. Continuous glucose monitoring functions as a negative feedback loop for individuals with type 2 diabetes. Ann Diabetes Metab Disorders Control. 2018;1(3):121.
- The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40(1):155-157.
- Polonsky WH, Fisher L, Hessler D, Edelman SV. Development of a new measure for assessing glucose monitoring device-related treatment satisfaction and quality of life. Diabetes Technol Ther. 2015;17(9):657-663.
- World Health Organization. The world health organization quality of life (WHOQOL)-BREF. No. WHO/HIS/HSI Rev. 2012.02. World Health Organization, 2004.
- Anderson RM, Funnell MM, Fitzgerald JT, Marrero DG. The Diabetes Empowerment Scale: a measure of psychosocial self-efficacy. Diabetes Care. 2000;23(6):739-743.
- Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diabetes Care. 2005;28(3):626-631.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
- Alexopoulos AS, Yancy WS, Edelman D, et al. Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. [Published online ahead of print October 25, 2019.] Chronic Illn. Doi:10.1177/1742395319884096
- Subar AF, Kirkpatrick SI, Mittl B, et al. The automated self-administered 24-hour dietary recall (ASA24): a resource for researchers, clinicians, and educators from the National Cancer Institute. J Acad Nutr Diet. 2012;112(8):1134-1137.
- Garcia JM, Cox D, Rice DJ. Association of physiological and psychological health outcomes with physical activity and sedentary behavior in adults with type 2 diabetes. BMJ Open Diabetes Res Care. 2017;5(1):e000306.
Source: PubMed